FDA approves first monthly injection of leppenketone long-acting needle to be available for treatment of adult schizophrenia

recently, the U.SFood andMedicines(
FDAapproved the first monthly injection of Perseris, Indivior, for the treatment of adult schizophreniamanufacturers of(it is noted that, by using a slow release technique, the concentration of the patient's lipeone blood drug remains stable for one month after a single injection of PerserisIt is worth mentioning that, unlike some of the sameproducts
, the first injection of Perseris can be directly at the desired blood concentration for treatment, withno delay, and patients do not need to use a load dose or take extra oral lipeoner for a period of time after the first injectionthe results of thePerseris were validated in a three-phase randomized double-blind placebo-controlled studythe study included 354 patients over a period of eight weeksThe results showed that on the 57th day of treatment, both the Perseris group's positive and negative symptom scale (PANSS) and the clinical overall impression-severe measurement table scored significantly betterThe drugmaker said the clinical study of Perseris was aimed at exploring whether Perseris could take on the therapeutic burden without using load doses and not taking extra oral lipeonesafetyPerseris' safety and tolerability performance is consistent with oral lipeoneThe most common systemic side effects were weight gain, sedation/drowsiness, and skeletal muscle pain, and the most common local reactions were injection pain and local skin rednesslike oral dosage forms, Perseris also carries a black-box warning that older patients with dementia-related psychosis have an increased mortality rate when using antipsychoticsThe drug was not approved for use in this patient groupPerseris can use 90mg or 120mg as a starting dose and should not be administered more than once a month (total dose 90mg or 120mg)carbamazepine and other cyP3A4 strong inducers may reduce the blood concentration of leppelone, and fluoxetine, paroxetine and other CYP2D6 strong inducers may increase the blood drug concentration of leppelketoneexposure to the drug in the late stages of pregnancy may cause symptoms of the neonatal cone in vitro and/or withdrawalpatients with liver and kidney insufficiency should first take lipoxacoone, carefully increase dissonance to 3 mg/d, and closely monitor it before using the drug